Tvardi Therapeutics Stock (NASDAQ:TVRD)
Previous Close
$3.44
52W Range
$2.75 - $43.65
50D Avg
$3.41
200D Avg
$10.36
Market Cap
$30.96M
Avg Vol (3M)
$48.99K
Beta
0.30
Div Yield
-
TVRD Company Profile
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).